In this study, we developed a novel anticancer PROTAC that activates STING-dependent antitumor immune responses via DAMP secretion from cancer cells and sensitizes B16-F10 tumors to anti-PD-1 antibody treatment. This evidence concerns the gene STING1 and cancer.